MAGE-A and NY-ESO-1 expression in cervical cancer : prognostic factors and effects of chemotherapy
Date Issued
2008-01-01
Author(s)
Napoletano, Chiara
Bellati, Filippo
Tarquini, Elisabetta
Tomao, Federica
Taurino, Federica
Rughetti, Aurelia
Muzii, Ludovico
Nuti, Marianna
Benedetti Panici, Pierluigi
DOI
10.1016/j.ajog.2007.05.019
Abstract
OBJECTIVE: The aim of this study was to evaluate the prevalence of cancer testis tumor-associated antigens MAGE-A and NY-ESO-1 in cervical cancer and correlate expression patterns with clinicopathologic parameters and prognosis. STUDY DESIGN: One hundred sixty-two cervical cancer samples from 109 patients who were treated with radical hysterectomy, neoadjuvant chemotherapy, or pelvic disease recurrence were analyzed by immunohistochemistry. RESULTS: MAGE-A was expressed by 32/94 (34%) and 7/15 (47%) previously untreated and recurrent tumors, respectively. NY-ESO-1 was expressed by 46/94 (49%) and 6/15 (40%) previously untreated and recurrent tumors, respectively. MAGE-A in early stage tumors was correlated to tumor size and lymph node metastases (P = .024 and P = .046, respectively) whereas NY-ESO-1 to tumor grading (P = .039). CONCLUSION: Cervical cancer frequently expresses cancer testis tumor-associated antigens. MAGE-A and NY-ESO-1 expression rates are not influenced by systemic therapies. Cancer testis tumor-associated antigens are correlated to common prognostic factors.